Form 4: Cytokinetics Executive Andrew Callos Sells 4,002 Shares of Common Stock

Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics, sold 4,002 shares of common stock at a price of $36.68 on May 5, 2025.

Summary

• On May 5, 2025, Andrew Callos, the EVP and Chief Commercial Officer of Cytokinetics Inc., sold 4,002 shares of the company's common stock.
• The transaction was executed at a price of $36.68 per share.
• Following the transaction, Mr. Callos directly owns 60,687 shares of Cytokinetics common stock.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of a stock sale by an executive. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

Executive stock sales are a common occurrence and are often related to personal financial planning rather than a reflection of the company's prospects. However, large or frequent sales can sometimes be viewed negatively by investors.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, depending on the size of the transaction and the context.

Key Dates

Keywords

Form 4, Cytokinetics, CYTK, Andrew Callos, Stock Sale, Executive, Beneficial Ownership